Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease - Concepedia

Concepedia

Publication | Closed Access

Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease

18

Citations

17

References

2024

Year

Philippe‐Antoine Bilodeau, Anastasia Vishnevetsky, Negar Molazadeh, Itay Lotan, Monique Anderson, Gabriela Romanow, Rebecca Salky, Brian C. Healy, Marcelo Matiello, Tanuja Chitnis,

Multiple Sclerosis Journal

Abstract

IVIG had the lowest ARRs and IRRs compared to pre-treatment and the highest relapse-freedom odds ratio compared to prednisone, while BCD had the lowest. In pediatric-onset MOGAD, MMF had the lowest ARRs.

References

	Year	Citations
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Journal of Neuroinflammation	2016	873
Clinical presentation and prognosis in MOG-antibody disease: a UK study Maciej Juryńczyk, Silvia Messina, Mark Woodhall, Brain Neurological DisorderImmunodeficienciesImmunologyDiagnosisPathology	2017	704
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Yael Hacohen, Yu Yi M. Wong, Christian Lechner, JAMA Neurology	2018	403
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Álvaro Cobo‐Calvo, Anne Ruiz, Fabien Rollot, Annals of Neurology	2020	242
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder John J. Chen, Eoin P. Flanagan, M. Tariq Bhatti, Neurology	2020	221
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients Daniel Whittam, Álvaro Cobo‐Calvo, A. Sebastian López‐Chiriboga, Multiple Sclerosis and Related Disorders MoxibustionAutoimmune DiseaseImmunodeficienciesImmunologyPathology	2020	165
Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease Álvaro Cobo‐Calvo, María Sepúlveda, Fabien Rollot, Journal of Neuroinflammation	2019	149
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders Marius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt, Neurology Neuroimmunology & Neuroinflammation	2021	134
Treatment of MOG antibody associated disorders: results of an international survey. Venkatraman Karthikeayan, Emily Gibbons, Rachel Kneen, Padua Research Archive (University of Padova)	2020	131
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders Alexis Montcuquet, Nicolas Collongues, Caroline Papeix, Multiple Sclerosis Journal	2016	111

Page 1